ArticleCureus2026
An Unusual Presentation of Dermatofibrosarcoma Protuberans (DFSP): The Role of Advanced Molecular Testing in Collagen Type I Alpha 1 Chain (COL1A1)-Negative Cases.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dermatofibrosarcoma protuberans (DFSP) is a rare, low-grade cutaneous fibroblastic sarcoma of the dermis that typically presents as a slow-growing red or violet colored plaque. It is classically driven by a collagen type I alpha 1 chain::platelet-derived growth factor subunit B (COL1A1::PDGFB) fusion and is characterized by indolent but locally infiltrative growth with a high risk of local recurrence. Here, we present a 39-year-old woman with a past medical history of breast cancer 1 (BRCA1)/ataxia-telangiectasia mutated (ATM) mutations and invasive lobular carcinoma of the left breast status post bilateral mastectomy, who presented with a tender right calf lump for one year. On physical exam, a well-circumscribed, mobile 2 cm mass was palpated in the right calf without overlying skin changes. Biopsy revealed a CD34-positive, low-grade, cellular, spindle cell neoplasm measuring 2.2 × 1.4 × 0.9 cm, extending to the biopsy margins. Histologically, DFSP is characterized by uniform spindle cells with diffuse CD34 staining. Loss of Rb staining was noted in lesional cells, an atypical finding that initially favored a diagnosis of lipoma over DFSP, complicating the initial differential. Fluorescence in situ hybridization (FISH) analysis for COL1A1 rearrangement was negative, necessitating advanced molecular testing. Solid tumor next-generation sequencing fusion panel identified a COL6A3::PDGFD gene fusion, which accounts for about 2% of DFSP cases. The histologic and molecular findings supported a diagnosis of DFSP with an uncommon translocation. The differential diagnosis included spindle cell lipoma and cellular fibrohistiocytic neoplasm, but these were excluded based on immunohistochemistry and genetic data. Given the extension of lesional cells to biopsy margins, re-excision was performed with negative margins. This case exhibits an atypical presentation of DFSP with a rare COL6A3::PDGFD fusion undetectable by standard FISH, demonstrating the importance of advanced molecular testing in suspected DFSP when FISH is negative for the COL1A1 rearrangement. Additionally, DFSP typically presents on the trunk with overlying skin surface changes, making a calf lesion without cutaneous involvement unusual.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.